EGFR and Cognitive impairment: Leukoencephalopathy and cognitive impairment were primary late toxicities in present study, and only history of EGFR-TKI treatment was a risk factor for grade 2 leukoencephalopathy in multivariate analysis, which had not been reported by other studies.